FDA Issued Complete Response Letter To Dynavax Saying SBLA For Four-Dose HEPLISAV-B Regimen Did Not Provide Sufficient Data To Support Full Evaluation Of Effectiveness Or Safety
FDA Issued Complete Response Letter To Dynavax Saying SBLA For Four-Dose HEPLISAV-B Regimen Did Not Provide Sufficient Data To Support Full Evaluation Of Effectiveness Or Safety
美国食品药品管理局向戴纳瓦克斯发布了完整的回复信，称四剂HEPLISAV-B方案的SBLA没有提供足够的数据来支持对有效性或安全性的全面评估
FDA Issued Complete Response Letter To Dynavax Saying SBLA For Four-Dose HEPLISAV-B Regimen Did Not Provide Sufficient Data To Support Full Evaluation Of Effectiveness Or Safety
美国食品药品管理局向戴纳瓦克斯发布了完整的回复信，称四剂HEPLISAV-B方案的SBLA没有提供足够的数据来支持对有效性或安全性的全面评估
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。